Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422265 · ClinicalTrials.gov registry record
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 56
- Enrollment target
NCT01422265 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 56 participants.
The verdict
NCT01422265 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred \> 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are currently in observation or undergoing bevacizumab maintenance treatment will be eligible to participate in the study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422265
The ClinicalTrials.gov registry entry for NCT01422265 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01422265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422265 about?
NCT01422265 is a clinical study titled "Patient Reported Symptoms in Ovarian Cancer (PRECISION)". This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred \> 6 months after first-line platinum-based...
What is the current status of trial NCT01422265?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2011-06. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01422265?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.